The RATIFY study has demonstrated benefit of combining midostaurin with standard induction and consolidation therapy of FLT3-mutated AML in patients less than 60 years of age, and we await results if this agent will become the first FDA-approved inhibitor in the upfront setting for younger AML patients. This evidence concerns the gene FLT3 and acute myeloid leukemia.